Using advanced machine learning to improve blood tests for detecting cancer
Official title: Advanced machine learning to empower ultra-sensitive liquid biopsy in melanoma and non-small cell lung cancer
Funded at Sloan-Kettering Inst Can Research · NIH-10881697 · Data updated 2026-11-12
This study is looking to improve blood tests that check for cancer signals in people with melanoma and non-small cell lung cancer, using advanced technology to catch things that regular tests might miss, so that doctors can better track how the cancer is doing and adjust treatments sooner for better results.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 4, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $292,597 |
| NIH project number | 5K08CA263301-02 |
| Project ID | NIH-10881697 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced melanoma or non-small cell lung cancer who are undergoing treatment.
✕Less likely to help
Patients with early-stage cancers or those not receiving treatment may not benefit from this research.
What this research studies
This research focuses on enhancing the sensitivity of liquid biopsies, which are blood tests that detect circulating tumor DNA (ctDNA) in patients with melanoma and non-small cell lung cancer. By employing whole genome sequencing and advanced machine learning techniques, the study aims to identify cancer signals that are often missed by traditional methods. The goal is to create a more accurate and timely way to monitor cancer progression and response to treatment, potentially allowing for earlier interventions and better patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective monitoring of cancer treatment, allowing for timely adjustments in therapy and improved patient survival rates.
How similar studies have gone: Previous research has shown promise in using advanced sequencing techniques for liquid biopsies, indicating that this approach could lead to significant advancements in cancer monitoring.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Widman, Adam — Sloan-Kettering Inst Can Research
- Study coordinator: Widman, Adam
Related research
Other NIH-funded projects on the same topics.
-
Advanced machine learning to improve blood-based cancer detection in melanoma and lung cancer
A physician-scientist is using cutting-edge AI to make blood tests for melanoma and non-small cell lung cancer much more sensitive, so doctors can monitor cancer without relying on scans.
-
Improving blood tests for early cancer detection and treatment monitoring in melanoma and lung cancer
This work aims to make blood tests much better at finding tiny amounts of cancer DNA to help people with melanoma and non-small cell lung cancer.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.